• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk-based management of prostate cancer.

作者信息

D'Amico Anthony V

出版信息

N Engl J Med. 2011 Jul 14;365(2):169-71. doi: 10.1056/NEJMe1103829.

DOI:10.1056/NEJMe1103829
PMID:21751910
Abstract
摘要

相似文献

1
Risk-based management of prostate cancer.基于风险的前列腺癌管理
N Engl J Med. 2011 Jul 14;365(2):169-71. doi: 10.1056/NEJMe1103829.
2
[High risk prostate cancer results of one year RT-HT].[一年放疗联合激素治疗的高危前列腺癌结果]
Prog Urol. 2005 Dec;15(6 Suppl 1):1256-61.
3
Long-term outcomes of 60 Gy conventional radiotherapy combined with androgen deprivation for localized or locally advanced prostate cancer.60Gy常规放疗联合雄激素剥夺治疗局限性或局部晚期前列腺癌的长期疗效。
Jpn J Clin Oncol. 2005 Nov;35(11):655-9. doi: 10.1093/jjco/hyi174. Epub 2005 Nov 7.
4
Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease.单纯近距离放射治疗或联合放疗、雄激素抑制治疗或两者同时使用时，高危疾病男性前列腺癌的死亡风险。
J Clin Oncol. 2009 Aug 20;27(24):3923-8. doi: 10.1200/JCO.2008.20.3992. Epub 2009 Jul 13.
5
Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.在接受局部前列腺癌放射治疗的男性中，新辅助雄激素剥夺治疗期间前列腺特异性抗原减半时间与生化控制相关。
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1022-8. doi: 10.1016/j.ijrobp.2009.12.029. Epub 2010 May 24.
6
Advanced prostate cancer. Hormonal treatment.晚期前列腺癌。激素治疗。
Tunis Med. 2005 Dec;83 Suppl 12:71-3.
7
Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.Ⅱ期临床试验：适形外照射放疗和高剂量率近距离放疗联合长期雄激素抑制治疗不适合前列腺癌的可行性报告。
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):386-92. doi: 10.1016/j.ijrobp.2009.01.059. Epub 2009 May 8.
8
Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.局限性前列腺癌近距离放疗男性患者中最大雄激素阻断与单一雄激素阻断及复发风险比较
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):36-9. doi: 10.1016/j.ijrobp.2008.10.059. Epub 2009 Feb 23.
9
[First line indications for hormonal therapy in prostate cancer].[前列腺癌激素治疗的一线适应症]
Prog Urol. 2010 Feb;20(2):109-15. doi: 10.1016/j.purol.2009.11.001. Epub 2009 Dec 22.
10
Hormonal treatment of prostate cancer.前列腺癌的激素治疗
N Engl J Med. 1999 Mar 11;340(10):812-3. doi: 10.1056/NEJM199903113401015.

引用本文的文献

1
Non-epithelial Circulating Tumor Cells Enhance Disease Progression in High-risk Prostate Cancer through EMT and COL1A1 Expression.非上皮循环肿瘤细胞通过上皮-间质转化和COL1A1表达促进高危前列腺癌的疾病进展。
Int J Med Sci. 2025 Feb 28;22(7):1562-1573. doi: 10.7150/ijms.107703. eCollection 2025.
2
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups.对392,522名男性前列腺特异性抗原水平的全基因组关联研究发现了新的基因座，并改善了不同祖先群体的预测。
Nat Genet. 2025 Feb;57(2):334-344. doi: 10.1038/s41588-024-02068-z. Epub 2025 Feb 10.
3
Prognostic Testing for Prostate Cancer-A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice.
前列腺癌的预后检测——一种成本效益分析，比较前列腺类型P评分生物标志物方法与标准临床实践。
Pharmacoeconomics. 2025 May;43(5):509-520. doi: 10.1007/s40273-024-01466-9. Epub 2025 Jan 11.
4
Imaging assessment of prostate cancer recurrence: advances in detection of local and systemic relapse.前列腺癌复发的影像学评估：局部和全身复发检测的进展
Abdom Radiol (NY). 2025 Feb;50(2):807-826. doi: 10.1007/s00261-024-04412-7. Epub 2024 Sep 10.
5
Prostate cancer risk stratification via eNose urine odor analysis: a preliminary report.通过电子鼻尿液气味分析进行前列腺癌风险分层：初步报告。
Front Oncol. 2024 Mar 5;14:1339796. doi: 10.3389/fonc.2024.1339796. eCollection 2024.
6
Diagnostic value of [Tc]Tc-PSMA-I&S-SPECT/CT for the primary staging and restaging of prostate cancer.[锝]Tc-PSMA-I&S-SPECT/CT对前列腺癌原发分期及再分期的诊断价值
Ther Adv Med Oncol. 2024 Jan 18;16:17588359231221342. doi: 10.1177/17588359231221342. eCollection 2024.
7
Genetically adjusted PSA levels for prostate cancer screening.前列腺癌筛查的基因调整 PSA 水平。
Nat Med. 2023 Jun;29(6):1412-1423. doi: 10.1038/s41591-023-02277-9. Epub 2023 Jun 1.
8
Observation, Radiotherapy, or Radical Prostatectomy for Localized Prostate Cancer: Survival Analysis in the United States.局限性前列腺癌的观察、放疗或根治性前列腺切除术：美国的生存分析
World J Mens Health. 2023 Oct;41(4):940-950. doi: 10.5534/wjmh.220151. Epub 2023 Mar 15.
9
Ex Vivo Fluorescence Confocal Microscopy (FCM) of Prostate Biopsies Rethought: Opportunities of Intraoperative Examinations of MRI-Guided Targeted Biopsies in Routine Diagnostics.前列腺活检的体外荧光共聚焦显微镜检查（FCM）再思考：MRI引导下靶向活检术中检查在常规诊断中的机遇
Diagnostics (Basel). 2022 May 5;12(5):1146. doi: 10.3390/diagnostics12051146.
10
A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality.基于三基因特征的新型风险评分（P评分）用于评估前列腺癌特异性死亡风险
Res Rep Urol. 2022 May 11;14:203-217. doi: 10.2147/RRU.S358169. eCollection 2022.